Search hospitals > Massachusetts > Methuen

Dana Farber-Merrimack Valley

Claim this profile
Methuen, Massachusetts 01844
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
11 reported clinical trials
1 medical researcher
Photo of Dana Farber-Merrimack Valley in MethuenPhoto of Dana Farber-Merrimack Valley in MethuenPhoto of Dana Farber-Merrimack Valley in Methuen

Summary

Dana Farber-Merrimack Valley is a medical facility located in Methuen, Massachusetts. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Cancer, Breast Cancer, Adenocarcinoma and other specialties. Dana Farber-Merrimack Valley is involved with conducting 11 clinical trials across 23 conditions. There are 1 research doctors associated with this hospital, such as Pedro M. Sanz-Altamira.

Area of expertise

1Non-Small Cell Lung Cancer
Dana Farber-Merrimack Valley has run 4 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I
2Lung Cancer
Dana Farber-Merrimack Valley has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Top PIs

Clinical Trials running at Dana Farber-Merrimack Valley

Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Esophageal Cancer
Rectal Cancer
Esophageal Adenocarcinoma
Cancer
ALK Gene Rearrangement
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Genetic Testing

for Early-Stage Lung Cancer

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Dana Farber-Merrimack Valley?
Dana Farber-Merrimack Valley is a medical facility located in Methuen, Massachusetts. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Cancer, Breast Cancer, Adenocarcinoma and other specialties. Dana Farber-Merrimack Valley is involved with conducting 11 clinical trials across 23 conditions. There are 1 research doctors associated with this hospital, such as Pedro M. Sanz-Altamira.